# Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects

> **NCT04309734** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Atea Pharmaceuticals, Inc.**

## Conditions studied

- Hepatitis C
- Hepatitis C, Chronic
- Chronic Hepatitis C
- Hepatitis C Virus Infection
- HCV Infection

## Interventions

- **DRUG:** AT-777
- **DRUG:** Placebo
- **DRUG:** AT-527

## Key facts

- **NCT ID:** NCT04309734
- **Lead sponsor:** Atea Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-10
- **Primary completion:** 2022-06
- **Final completion:** 2022-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn prior to study initiation.
- **Last updated:** 2022-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04309734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04309734, "Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04309734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*